{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Jade Biosciences, Inc."},"Symbol":{"label":"Symbol","value":"JBIO"},"Address":{"label":"Address","value":"930 WINTER STREET,SUITE M-500, WALTHAM, Massachusetts, 02451, United States"},"Phone":{"label":"Phone","value":"+1 617 443-2400"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Jade Biosciences is focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Its lead asset, JADE-001, targets the cytokine APRIL for immunoglobulin A nephropathy, with initiation of a first-in-human clinical trial expected in the second half of 2025. Jade's pipeline also includes two undisclosed antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount."},"CompanyUrl":{"label":"Company Url","value":"https://www.aerovatetx.com"}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}